Antibody

100개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved100 programs
AntibodyLimited DatastaleRochePhase 3

trastuzumab (TX05, TX05 (trastuzumab))

Breast Cancer; Breast Neoplasms · HER2

#HER2#Antibody#Phase3#monoclonal-antibody#BreastCancer+2
Trials 1Status Active
AntibodyLimited DatastaleFudan UniversityPhase 2

trastuzumab (Herceptin, Taxanes combined with trastuzumab and pertuzumab.)

Advanced HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedHER2-positiveBreastCance+1
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab （12weeks） (Toripalimab （12weeks）)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab （18weeks） (Toripalimab （18weeks）)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleNorthwestern UniversityPhase 1

Transferrin Receptor-Targeted Liposomal p53 cDNA (Transferrin Receptor-Targeted Liposomal p53 cDNA)

Anatomic Stage IV Breast Cancer AJCC v8; Breast Inflammatory Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8

#AnatomicStageIVBreastCancerAJCCv#Antibody#Phase1#monoclonal-antibody#BreastInflammatoryCarcinoma+1
Trials 1Status Discontinued
AntibodyLimited DatastaleAstraZenecaPhase 2

Tremelimumab monotherapy (Tremelimumab monotherapy)

Urothelial Bladder Cancer; Triple-negative Breast Cancer · Urothelial Bladder Cancer

#UrothelialBladderCancer#Antibody#Phase2#monoclonal-antibody#Triple-negativeBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleQuantumLeap Healthcare Collabor…Phase 2

trastuzumab (Herceptin, Trilaciclib with or without trastuzumab + pertuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedSolidTumors+2
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedSolidTumors+2
Trials 1Status Recruiting
AntibodyLimited DatastaleMerus B.V.Phase 2

Zenocutuzumab (Zenocutuzumab)

Breast Cancer Metastatic · Breast Cancer Metastatic

#BreastCancerMetastatic#Antibody#Phase2#monoclonal-antibody#Merus
Trials 1Status Active
AntibodyLimited DatastaleJules Bordet InstitutePhase 1

trastuzumab (Herceptin, Zr89-trastuzumab)

Breast Neoplasms; Secondary · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, capecitabine and trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleThe Netherlands Cancer InstitutePhase 1

atezolizumab (Tecentriq, carbplatin, cyclophophamide, atezolizumab)

Breast Cancer; Cervix Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#monoclonal-antibody#CervixCancer+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

THP (investigator-selected taxane/trastuzumab/pertuzumab, investigator-selected taxane/trastuzumab/pertuzumab (THP))

Neoadjuvant Therapies for HER2+ Breast Cancer · HER2

#HER2#Antibody#Phase3#monoclonal-antibody#NeoadjuvantTherapiesforHER2+Brea+1
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

ixabepilone + cetuximab (ixabepilone + cetuximab)

Triple Negative Locally Advanced Non-resectable Breast Cancer; Metastatic Breast Cancer · Triple Negative Locally Advanced Non-res

#TripleNegativeLocallyAdvancedNon#Antibody#Phase2#monoclonal-antibody#MetastaticBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleCytoDyn, Inc.Preclinical

PRO 140 (leronlimab, leronlimab (PRO 140))

TNBC; TNBC - Triple-Negative Breast Cancer · TNBC

#TNBC#Antibody#Preclinical#monoclonal-antibody#TNBC-Triple-NegativeBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

P (pertuzumab, pertuzumab (P))

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy)

HER2-positive Breast Cancer; Neoadjuvant Therapy · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#HER2-positiveBreastCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu Hengrui Pharmaceutical …Phase 2

trastuzumab (Herceptin, pyrotinib combined with trastuzumab, dalpiciclib and letrozole)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Jiangsu
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, vinorelbine and trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting

5 / 5 pages

← PreviousNext →